Analyst Brandon Couillard from Wells Fargo maintained a Hold rating on Revvity (RVTY – Research Report) and keeping the price target at $102.00.
Brandon Couillard has given his Hold rating due to a combination of factors surrounding Revvity’s recent performance and future outlook. The company’s first-quarter results showed organic revenue growth of 4%, which was slightly above market expectations, and an earnings per share (EPS) that exceeded consensus due to a lower tax rate. However, despite these positive aspects, the outlook for operating margins has been adjusted downward, which could impact profitability.
Furthermore, while there was solid growth in certain segments such as reagents and diagnostics, the performance of life science instruments lagged, raising concerns about the sustainability of growth in some areas. The company’s guidance for 2025 remains unchanged in terms of EPS, but the potential headwinds from foreign exchange and a slight contraction in operating margins suggest a cautious approach. These mixed signals contribute to the decision to maintain a Hold rating, reflecting a balanced view of the company’s prospects.
According to TipRanks, Couillard is a 5-star analyst with an average return of 14.1% and a 57.88% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Bruker, Danaher, and Revvity.
In another report released yesterday, Jefferies also maintained a Hold rating on the stock with a $106.00 price target.